Immunovant, Inc. (IMVT)
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Ticker
- IMVT
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $6.30B
- 52-week range
- $21.43 - $45.42
Valuation
- Share price
- $30.53 (close of Nov 6, 2026)
- P/E (TTM)
- -10.86x
- Price to book
- 8.56x
- Price to free cash flow
- -15.20x
- Enterprise value
- $5.50B
- Book value per share
- $3.57
Price performance
| Period | Change |
|---|---|
| 1 day | +7.54% |
| 5 days | +4.66% |
| 1 month | -4.92% |
| 3 months | -23.18% |
| 6 months | +6.49% |
| Year to date | +20.10% |
| 1 year | +28.98% |
| 3 years | -9.51% |
| 5 years | +255.83% |
| All time | +206.83% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 19.91%
- Shares short
- 18.27M
- Days to cover
- 12.35
- Change since prior report
- +4.92%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -59.30%
- Return on invested capital
- -62.24%*
- Return on assets
- -52.83%
- Return on capital employed
- -62.25%*
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -6.58%
- Current ratio
- 7.27x
- Net debt to EBITDA
- 1.41x
Latest reported year
- Period end
- Mar 31, 2026
- Fiscal year
- 2026
- EBITDA
- -$504.98M
- Net income
- -$505.61M
- Earnings per share
- $-2.77
- Research and development
- $456.66M
- Shares outstanding
- 182.42M
Income statement by year
| Period end | Net income | EPS |
|---|---|---|
| 2026-03-31 | -$505.61M | -$2.77 |
| 2025-03-31 | -$413.84M | -$2.73 |
| 2024-03-31 | -$259.34M | -$1.88 |
| 2023-03-31 | -$210.96M | -$1.71 |
| 2022-03-31 | -$156.73M | -$1.43 |
| 2021-03-31 | -$107.43M | -$1.22 |
| 2020-03-31 | -$66.39M | -$1.54 |
| 2019-03-31 | -$28.60M | -$1.29 |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|---|---|
| 2026-03-31 | -59.30% | -62.24%* |
| 2025-03-31 | -58.50% | -61.86%* |
| 2024-03-31 | -41.98% | -45.92%* |
| 2023-03-31 | -58.20% | -60.08%* |
| 2022-03-31 | -33.36% | -33.19%* |
| 2021-03-31 | -27.44% | -27.20%* |
| 2020-03-31 | -70.57% | -69.81%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash |
|---|---|
| 2026-03-31 | $902.11M |
| 2025-03-31 | $713.97M |
| 2024-03-31 | $635.37M |
| 2023-03-31 | $376.53M |
| 2022-03-31 | $493.82M |
| 2021-03-31 | $400.15M |
| 2020-03-31 | $100.57M |
| 2019-03-31 | $6.99M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2026-03-31 | -$407.32M | $55.72M |
| 2025-03-31 | -$376.63M | $49.49M |
| 2024-03-31 | -$214.59M | $41.12M |
| 2023-03-31 | -$188.39M | $32.30M |
| 2022-03-31 | -$106.37M | $34.24M |
| 2021-03-31 | -$83.54M | $18.82M |
| 2020-03-31 | -$53.39M | $6.96M |
| 2019-03-31 | -$28.60M | $1.31M |
| 2018-03-31 | -$128.30M | - |
Investor relations
Next earnings report
- Next confirmed report
- Nov 9, 2026
- Consensus EPS estimate
- $-0.73
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-06 | Jun 2026 | -$0.66 |
| 2026-05-20 | Mar 2026 | -$0.60 |
| 2026-02-06 | Dec 2025 | -$0.72 |
| 2025-11-10 | Sep 2025 | -$0.72 |
| 2025-08-11 | Jun 2025 | -$0.69 |
| 2025-05-29 | Mar 2025 | -$0.72 |
| 2025-02-06 | Dec 2024 | -$0.73 |
| 2024-11-07 | Sep 2024 | -$0.61 |
Filings and sources
- Company website
- immunovant.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades